Provided by Tiger Trade Technology Pte. Ltd.

MAIA Biotechnology Inc.

1.97
+0.06003.14%
Post-market: 1.970.00000.00%19:59 EST
Volume:544.47K
Turnover:1.08M
Market Cap:72.95M
PE:-2.56
High:2.05
Open:1.96
Low:1.94
Close:1.91
52wk High:3.19
52wk Low:0.8700
Shares:37.03M
Float Shares:28.34M
Volume Ratio:0.79
T/O Rate:1.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7683
EPS(LYR):-1.0476
ROE:-2691.07%
ROA:-148.38%
PB:1750.75
PE(LYR):-1.88

Loading ...

MAIA Biotechnology outlines 2026 goals for ateganosine program

TIPRANKS
·
Jan 21

MAIA Biotechnology highlights milestones, catalysts for FY26

TIPRANKS
·
Jan 20

Maia Biotechnology Reports Strong 2025 Progress and Outlines 2026 Clinical Milestones for Ateganosine

Reuters
·
Jan 20

MAIA Biotechnology Highlights Strategy in New Investor Presentation

TIPRANKS
·
Jan 14

Director Stan Smith Reports Acquisition of Maia Biotechnology Inc. Common Shares

Reuters
·
Jan 12

MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings

GlobeNewswire
·
Dec 24, 2025

Director Stan Smith Reports Acquisition of Maia Biotechnology Inc. Common Shares

Reuters
·
Dec 23, 2025

Director Ngar Yee Louie Acquires Common Shares of Maia Biotechnology Inc

Reuters
·
Dec 23, 2025

MAIA Biotechnology Announces $1.51 Million Private Placement

GlobeNewswire
·
Dec 17, 2025

MAIA’s Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates

GlobeNewswire
·
Dec 12, 2025

Maia Biotechnology Announces First Patient Dosed in Thio-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer

THOMSON REUTERS
·
Dec 11, 2025

Maia Biotechnology Executives Acquire 182,445 Shares in Insider Buying Spree

Reuters
·
Dec 11, 2025

Maia Biotechnology Unveils Breakthrough Telomere-Targeting Therapy for Resistant Lung Cancer

Reuters
·
Dec 11, 2025

Director Stan Smith Reports Acquisition of Maia Biotechnology Inc. Common Shares

Reuters
·
Dec 10, 2025

BRIEF-Maia Biotechnology Announces Open Market Purchases By CEO And Directors

Reuters
·
Dec 01, 2025

Maia Biotechnology Announces Open Market Purchases by CEO and Directors

THOMSON REUTERS
·
Dec 01, 2025

Maia Biotechnology Inc - CEO Vlad Vitoc Purchases 94,300 Shares at $1.08 Each

THOMSON REUTERS
·
Dec 01, 2025

Maia Biotechnology Inc - Board Members Purchase 88,145 Shares at $1.04 Each

THOMSON REUTERS
·
Dec 01, 2025

Director Stan Smith Reports Acquisition of Common Shares in Maia Biotechnology Inc

Reuters
·
Dec 01, 2025

CEO’s Bold Move: Major Stock Purchase at MAIA Biotechnology!

TIPRANKS
·
Nov 29, 2025